EGFR mutations and EGFR tyrosine kinase inhibition in non-small cell lung cancer |
| |
Authors: | Miller Vincent A |
| |
Institution: | Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. millerv@mskcc.org |
| |
Abstract: | OBJECTIVES: To discuss selected molecular targets and new clinical variables that can serve as both predictive and prognostic markers for outcome in patients with non-small cell lung cancer (NSCLC) treated with EGFR-TKIs. DATA SOURCES: Research and journal articles. CONCLUSION: In the near future, treatment for NSCLC will rely ever increasingly on molecular targets rather than empirically chosen cytotoxic chemotherapy for some patients. This will improve outcomes for patients with NSCLC. IMPLICATIONS FOR NURSING PRACTICE: An understanding of the molecular targets and clinical variables that are predictive and prognostic of outcome in NSCLC will help nurses better care for these patients. |
| |
Keywords: | Epidermal growth factor receptor (EGFR) kirsten ras (KRAS) EGFR mutation oncogene addiction erlotinib gefitinib |
本文献已被 ScienceDirect PubMed 等数据库收录! |